Equities analysts expect that Exelixis, Inc. (NASDAQ:EXEL) will post earnings per share of $0.12 for the current quarter, according to Zacks. Six analysts have made estimates for Exelixis’ earnings. The highest EPS estimate is $0.17 and the lowest is $0.07. Exelixis also reported earnings per share of $0.12 during the same quarter last year. The business is expected to announce its next quarterly earnings results on Monday, February 26th.
According to Zacks, analysts expect that Exelixis will report full year earnings of $0.49 per share for the current financial year, with EPS estimates ranging from $0.44 to $0.51. For the next financial year, analysts expect that the firm will post earnings of $0.72 per share, with EPS estimates ranging from $0.42 to $1.24. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Exelixis.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.18. The firm had revenue of $152.50 million for the quarter, compared to analyst estimates of $104.91 million. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The business’s quarterly revenue was up 145.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.04) earnings per share.
In related news, insider Gisela Schwab sold 100,000 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $23.79, for a total transaction of $2,379,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Stelios Papadopoulos sold 200,000 shares of the firm’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $27.68, for a total transaction of $5,536,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 870,152 shares of company stock worth $23,244,457. 5.10% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. First Quadrant L P CA grew its position in shares of Exelixis by 6,771.4% in the third quarter. First Quadrant L P CA now owns 402,528 shares of the biotechnology company’s stock valued at $9,753,000 after purchasing an additional 396,670 shares during the period. Prudential Financial Inc. grew its position in shares of Exelixis by 262.0% in the second quarter. Prudential Financial Inc. now owns 627,530 shares of the biotechnology company’s stock valued at $15,456,000 after purchasing an additional 454,197 shares during the period. GAM Holding AG acquired a new stake in shares of Exelixis in the second quarter valued at about $1,256,000. Macquarie Group Ltd. acquired a new stake in shares of Exelixis in the second quarter valued at about $3,449,000. Finally, Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Exelixis by 583.1% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 659,592 shares of the biotechnology company’s stock valued at $16,246,000 after purchasing an additional 563,040 shares during the period. Institutional investors and hedge funds own 81.19% of the company’s stock.
Exelixis (EXEL) traded down $0.69 during trading hours on Friday, hitting $26.42. 2,103,300 shares of the stock were exchanged, compared to its average volume of 4,082,505. The firm has a market capitalization of $8,020.58, a price-to-earnings ratio of 53.16, a P/E/G ratio of 1.22 and a beta of 1.89. Exelixis has a 1 year low of $14.22 and a 1 year high of $32.50.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.